Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
PolyMedica probe: SEC investigation into alleged Medicare over-billing has been terminated, company announces April 8. "No enforcement action has been recommended" by the SEC to the oversight committee that was looking into the alleged fraud (1"The Gray Sheet" Aug. 13, 2001, p. 14), PolyMedica says. "We will continue to cooperate with the Department of Justice with regard to its investigation into the company as well." News of the terminated investigation sent the stock up 53%, to close at $38.90 the day of the announcement...
You may also be interested in...
PolyMedica Accounting Practice Draws Shareholder Class Action Suits
PolyMedica will change its accounting practices after discussions with the Securities & Exchange Commission over the method the firm employs to capitalize its advertising costs
PolyMedica Accounting Practice Draws Shareholder Class Action Suits
PolyMedica will change its accounting practices after discussions with the Securities & Exchange Commission over the method the firm employs to capitalize its advertising costs
Polymedica probe
U.S. attorney in Miami with assistance from the FBI and HHS Inspector General are investigating allegations of fraud, improper revenue recognition and obstruction of justice by the DME distributor, Polymedica notes in a 10-Q filed with the Securities & Exchange Commission. Both civil and criminal investigations are being conducted, and the company says it is cooperating. In June, the U.S. attorney for Southern Illinois also issued a subpoena to the Woburn, Massachusetts firm's Liberty Medical unit concerning documents related to Medicare reimbursement of "depth shoes and inserts," the filing states. In April, the SEC completed an investigation of Polymedica related to Medicare over-billing, declining to recommend further action (11"The Gray Sheet" April 15, 2002, p. 22)...